A-Hydrocort Side Effects
Generic name: hydrocortisone
Note: This document contains side effect information about hydrocortisone. Some of the dosage forms listed on this page may not apply to the brand name A-Hydrocort.
Some side effects of A-Hydrocort may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to hydrocortisone: oral suspension, oral tablet
Along with its needed effects, hydrocortisone (the active ingredient contained in A-Hydrocort) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking hydrocortisone:More common
- blurred vision
- decrease in the amount of urine
- fast, slow, pounding, or irregular heartbeat or pulse
- mental depression
- mood changes
- noisy, rattling breathing
- numbness or tingling in the arms or legs
- pounding in the ears
- shortness of breath
- swelling of the fingers, hands, feet, or lower legs
- trouble thinking, speaking, or walking
- troubled breathing at rest
- weight gain
- Abdominal cramping and/or burning (severe)
- abdominal pain
- bloody, black, or tarry stools
- cough or hoarseness
- darkening of skin
- decrease in height
- decreased vision
- dry mouth
- eye pain
- eye tearing
- facial hair growth in females
- fever or chills
- flushed, dry skin
- fruit-like breath odor
- full or round face, neck, or trunk
- heartburn and/or indigestion (severe and continuous)
- increased hunger
- increased thirst
- increased urination
- loss of appetite
- loss of sexual desire or ability
- lower back or side pain
- menstrual irregularities
- muscle pain or tenderness
- muscle wasting or weakness
- pain in back, ribs, arms, or legs
- painful or difficult urination
- skin rash
- trouble healing
- trouble sleeping
- unexplained weight loss
- unusual tiredness or weakness
- vision changes
- vomiting of material that looks like coffee grounds
Some side effects of hydrocortisone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Increased appetite
- Abnormal fat deposits on the face, neck, and trunk
- dry scalp
- lightening of normal skin color
- red face
- reddish purple lines on the arms, face, legs, trunk, or groin
- swelling of the stomach area
- thinning of the scalp hair
For Healthcare Professionals
Applies to hydrocortisone: compounding powder, injectable powder for injection, injectable solution, injectable suspension, oral suspension, oral tablet, rectal foam with applicator, rectal suspension
Corticosteroid complications are primarily dose and duration of therapy dependent. Adverse effects have occurred less frequently at physiologic or lower pharmacologic dosages.
Adverse effects associated with duration of corticosteroid therapy include those occurring during short-term therapy (up to three weeks) or those occurring during long-term therapy (greater than three weeks).
Short-term effects have included sodium retention-related weight gain and fluid accumulation, hyperglycemia and glucose intolerance, hypokalemia, gastrointestinal upset and ulceration, reversible depression of the hypothalamus-pituitary-adrenal axis, and mood changes including mild euphoria and insomnia, nervousness, restlessness, mania, catatonia, depression, delusions, hallucinations, and violent behavior.
Long-term effects have included hypothalamus-pituitary-adrenal activity suppression, Cushingoid appearance, hirsutism or virilism, impotence, menstrual irregularities, peptic ulcer disease, cataracts and increased intraocular pressure/glaucoma, myopathy, osteoporosis, and vertebral compression fractures.
Cardiovascular effects such as hypertension and congestive heart failure due to long-term fluid retention as well as direct vascular effects have occurred during corticosteroid therapy.
Endocrine effects such as decreased glucose tolerance and hyperglycemia resulting in diabetes-like symptoms have occurred. Hypothalamus-pituitary-adrenal activity has been suppressed up to 12 months following long-term corticosteroid administration. Cushingoid appearance commonly has occurred with chronic therapy. Hirsutism or virilism, impotence, and menstrual irregularities may occur.
Corticosteroid therapy may induce glucose intolerance by reducing the utilization of glucose in tissues and increasing hepatic glucose output. Diabetes mellitus requiring diet modifications and hypoglycemic agents has developed in some patients.
Adrenal suppression can persist for up to twelve months after long-term corticosteroid therapy. Giving corticosteroids once a day or once every other day may reduce adrenal suppression. After corticosteroid therapy has been tapered, supplemental corticosteroid therapy during times of physical stress may be required.
Gastrointestinal effects of corticosteroid therapy have included gastrointestinal upset, nausea, vomiting, and peptic ulcer disease. Pancreatitis, ulcerative esophagitis, gastrointestinal perforation and hemorrhage have also been reported.
Gastrointestinal effects most commonly occurring during corticosteroid therapy have included nausea, vomiting, dyspepsia, and anorexia. Peptic ulcer disease has been associated with long-term corticosteroid therapy, but is relatively uncommon. Routine prophylactic therapy is not warranted in all individuals. Aluminum/magnesium-containing antacids generally have been used to manage GI complaints without significant drug interactions.
Metabolic adverse effects including hypernatremia (rare), hypokalemia, fluid retention, negative nitrogen balance and increased blood urea nitrogen concentration have occurred during corticosteroid therapy. Glucocorticoids have been reported to decrease the secretion of thyrotropin (TSH).
Musculoskeletal effects of corticosteroid therapy including myopathy, osteoporosis, vertebral compression fractures, tendon rupture (particularly the Achilles tendon), and aseptic necrosis of bone have been reported. Aseptic necrosis has been reported most often to affect the femoral head.
Corticosteroid myopathy has presented as weakness and wasting of the proximal limb and girdle muscles and generally has been reversible following cessation of therapy.
Corticosteroids inhibit intestinal absorption and increase urinary excretion of calcium leading to bone resorption and bone loss. Postmenopausal females are at risk of loss of bone density. Sixteen percent of elderly patients treated with corticosteroids for 5 years may experience vertebral compression fractures.
Immunologic effects of corticosteroid therapy have included impairment in cell-mediated immunity and increased susceptibility to bacterial, viral, fungal and parasitic infections. Immune response to skin tests may be suppressed.
Hepatic effects such as reversible increases in serum transaminase and alkaline phosphatase concentrations have occurred during corticosteroid therapy.
Hematologic effects have included thrombocytopenia, lymphopenia, and platelet alterations resulting in thrombolic events.
Dermatologic effects occurring during corticosteroid therapy have included increased ease in bruising, ecchymosis, petechiae striae, delayed wound healing, and acne.
Ocular changes with corticosteroid therapy have included increased intraocular pressure, glaucoma, and posterior subcapsular cataracts.
Psychiatric effects including psychoses, personality or behavioral changes, and pseudotumor cerebri have occurred/been exacerbated during corticosteroid therapy.
Bronchospasm after intravenous hydrocortisone (the active ingredient contained in A-Hydrocort) has been reported in some patients with aspirin-sensitive respiratory disease. A challenge study with oral aspirin followed with 100 mg hydrocortisone (IV) resulted in respiratory reactions to aspirin in 45 of 53 patients. These 45 patients then received a hydrocortisone challenge. No naso-ocular, dermal, or respiratory reactions were noted in 44 of 45 patients administered hydrocortisone. One aspirin-sensitive patient experienced bronchospasm and naso-ocular reactions to hydrocortisone and naso-ocular with minimal bronchospasm with methylprednisolone. Following aspirin desensitization and while on maintenance aspirin therapy, this patient again reacted with similar symptoms to hydrocortisone.
Case reports of hypersensitivity reactions to corticosteroids have been relatively uncommon. Side effects have included bronchospasm, shock, urticaria, and angioedema. Cross-reactivity between aspirin and hydrocortisone in patients with aspirin-sensitive respiratory disease has been suggested as the mechanism in patients with asthma, however data are controversial. Anaphylaxis has been most frequently associated with rapid injection or infusion of a high dose of corticosteroid. Reactions may be mediated by an immune or nonimmune mechanism.
Pseudorheumatism or glucocorticoid-withdrawal syndrome not related to adrenal insufficiency has occurred on withdrawal of corticosteroids. Patients experienced anorexia, nausea, vomiting, lethargy, headache, fever, arthralgias, myalgias, and postural hypotension. Symptoms resolved when corticosteroid therapy was reinstated.
More A-Hydrocort resources
- A-Hydrocort Prescribing Information (FDA)
- Hydrocortisone Professional Patient Advice (Wolters Kluwer)
- Hydrocortisone Prescribing Information (FDA)
- Hydrocortisone Monograph (AHFS DI)
- Colocort foam, enema Concise Consumer Information (Cerner Multum)
- Colocort Prescribing Information (FDA)
- Colocort enema MedFacts Consumer Leaflet (Wolters Kluwer)
- Cortef Prescribing Information (FDA)
- Cortef Concise Consumer Information (Cerner Multum)
- Cortef MedFacts Consumer Leaflet (Wolters Kluwer)
- Cortef Advanced Consumer (Micromedex) - Includes Dosage Information
- Cortenema Prescribing Information (FDA)
- Cortifoam Prescribing Information (FDA)
- Cortifoam foam MedFacts Consumer Leaflet (Wolters Kluwer)
- Hydrocortisone Buteprate topical Monograph (AHFS DI)
- Solu-Cortef Prescribing Information (FDA)
- Solu-Cortef solution MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.